Abstract 2150P
Background
VTE is a major, preventable complication in cancer patients (pts) and the second cause of mortality. Our aim is to describe clinical and pathological features of cancer pts with VTE and compare them to pts without VTE.
Methods
A retrospective case-control study of cancer pts with VTE diagnosed in 2022 at Vall Hebron Hospital (cases) and cancer pts without VTE treated at same centre (controls) was conducted. Clinical features including cancer site, stage, pathological/molecular profile, and therapy were registered; univariate analysis was performed.
Results
85 cases and 100 controls were analysed. Cases characteristics: 53% females, mean age 61. Most common cancers shown in the table. Cancer was locally advanced/metastatic in 78.8%. According to Khorana score, 75.3% had intermediate/high risk for VTE. Most common histology in lung was adenocarcinoma (ADK) (72.7%); 14.3% EGFR mutated. In breast, 93.3% were invasive ductal carcinomas (IDC), 93.3% expressed hormone receptors (HR), 40% HER2 positive, 6.7% germline BRCA mutation. All CRC were ADKs, 40% RAS mutations and 13% microsatellite instability (MSI). 82.4% of pts received chemotherapy (CT), 16.5% immunotherapy (IO), 15.3% hormone therapy (HT), 12.9% antiangiogenics, 10.6% tyrosine kinase inhibitors. Comparative analysis (Table): female sex was associated with VTE (Odds Ratio [OR], 2; 95%CI, 1.1-3.6). As to cancer type, only breast was associated with VTE (OR, 2.6; 95%CI, 1.01-6.8). Conversely, head and neck cancers had negative association with VTE (OR, 0.2; 95%CI, 0.04-0.9). No differences were observed regarding cancer stage. CT (OR, 6.72; 95%CI, 3.4-13.3), HT (OR, 3.4; 95%CI, 1.2-10.1) and targeted therapies (OR, 3.06; 95%CI 1.43-6.56) were associated with VTE; IO was not. Table: 2150P
Characteristics of cases and controls
Characteristic | VTE cases (N=85) | Controls (N=100) | P value |
Tumour site – no. (%) | |||
Lung | 18 (21,3%) | 30 (30%) | 0.172 |
Breast | 14 (16,47%) | 7 (7%) | 0.043* |
CRC | 12 (14,21%) | 13 (13%) | 0.825 |
Pancreas | 9 (10,59%) | 4 (4%) | 0.081 |
Gynaecological | 9 (10,59%) | 8 (8%) | 0.544 |
Gastroesophageal | 4 (4,71%) | 6 (6%) | 0.726 |
Genitourinary | 3 (3,53%) | 6 (6%) | 0.436 |
Head and neck | 2 (2,35%) | 11 (11%) | 0.022* |
Stage – no. (%) | |||
I | 3 (3,53%) | 6 (6%) | 0.436 |
II | 13 (15,29%) | 10 (10%) | 0.277 |
III | 21 (24,71%) | 21 (21%) | 0.549 |
IV | 46 (54,12%) | 59 (59%) | 0.504 |
Systemic therapies – no. (%) | |||
CT | 70 (82,35%) | 41 (41%) | <0.001* |
Targeted therapy | 25 (29,41%) | 12 (12%) | 0.003* |
IO | 14 (16,47%) | 11 (11%) | 0.278 |
HT | 13 (15,29%) | 5 (5%) | 0.019* |
Conclusions
Most common cancers in pts with VTE were lung (14% EGFR mutated), breast (HR positive 93%; HER2 positive 40%) and CRC (40% RAS mutated). Female sex and breast cancer were associated to VTE. CT, HT and targeted therapies were all associated with VTE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07